341 related articles for article (PubMed ID: 16700399)
21. Maternal serum-integrated screening for trisomy 18 using both first- and second-trimester markers.
Palomaki GE; Neveux LM; Knight GJ; Haddow JE
Prenat Diagn; 2003 Mar; 23(3):243-7. PubMed ID: 12627428
[TBL] [Abstract][Full Text] [Related]
22. [Comment on the contribution by Benz et al.: Serum screening for Down syndrome in women under 35 years of age with an age independent index].
Reynolds T; Pistorius K; Spencer K; John R
Z Geburtshilfe Neonatol; 1995; 199(3):128-9. PubMed ID: 7553259
[No Abstract] [Full Text] [Related]
23. Prenatal biochemical diagnostics of inborn developmental defects.
Malbohan I; Fialová L; Mikulíková L; Hájek Z
Sb Lek; 1994; 95(4):277-83. PubMed ID: 8867698
[TBL] [Abstract][Full Text] [Related]
24. Maternal serum screening for fetal trisomy 18: benefits of patient-specific risk protocol.
Hogge WA; Fraer L; Melegari T
Am J Obstet Gynecol; 2001 Aug; 185(2):289-93. PubMed ID: 11518881
[TBL] [Abstract][Full Text] [Related]
25. Prevention of Down syndrome: the Jerusalem experience.
Bach G; Ben-Neriah Z; Sagi M
Isr J Med Sci; 1993 Aug; 29(8):468-70. PubMed ID: 7691779
[No Abstract] [Full Text] [Related]
26. Are Down syndrome fetuses detected through maternal serum screening similar to those remaining undetected?
Christiaens GC; Hagenaars AM; Akkerman C; De France HF
Prenat Diagn; 1996 May; 16(5):437-42. PubMed ID: 8844002
[TBL] [Abstract][Full Text] [Related]
27. [Health Council of Netherlands recommendation 'Serum screening for risk assessment of Down syndrome for all women' poorly supported].
Hamerlynck JV; Knuist M
Ned Tijdschr Geneeskd; 2001 Oct; 145(42):2014-7. PubMed ID: 11695097
[TBL] [Abstract][Full Text] [Related]
28. [Maternal serum screening for congenital abnormalities and Down syndrome in Sønderjylland County. Eight years of experience].
Christiansen M; Petersen PL; Permin M; Larsen LA; Nørgaard-Pedersen B
Ugeskr Laeger; 1999 Dec; 161(50):6928-34. PubMed ID: 10643380
[TBL] [Abstract][Full Text] [Related]
29. [The triple-serum test for detection of Down syndrome and neural tube defects; the problem of a risk assessment test].
van den Boer-van den Berg JM; Dupuis HM
Ned Tijdschr Geneeskd; 1993 Jun; 137(26):1286-9. PubMed ID: 7688445
[No Abstract] [Full Text] [Related]
30. First- and second-trimester screening: detection of aneuploidies other than Down syndrome.
Breathnach FM; Malone FD; Lambert-Messerlian G; Cuckle HS; Porter TF; Nyberg DA; Comstock CH; Saade GR; Berkowitz RL; Klugman S; Dugoff L; Craigo SD; Timor-Tritsch IE; Carr SR; Wolfe HM; Tripp T; Bianchi DW; D'Alton ME;
Obstet Gynecol; 2007 Sep; 110(3):651-7. PubMed ID: 17766613
[TBL] [Abstract][Full Text] [Related]
31. Second trimester serum markers.
Canick JA; MacRae AR
Semin Perinatol; 2005 Aug; 29(4):203-8. PubMed ID: 16104669
[TBL] [Abstract][Full Text] [Related]
32. The sensitivity of the trivariate analysis using maternal serum alpha-feto protein, human chorionic gonadotrophin and maternal age in screening for fetal aneuploidy in mothers above the age of 35.
Anandakumar C; Chew S; Wong YC; Goh VH; Tain CF; Ratnam SS
J Perinat Med; 1999; 27(3):178-82. PubMed ID: 10503178
[TBL] [Abstract][Full Text] [Related]
33. Using record linkage and manual follow-up to evaluate the Victorian maternal serum screening quadruple test for Down's syndrome, trisomy 18 and neural tube defects.
Jaques AM; Collins VR; Haynes K; Sheffield LJ; Francis I; Forbes R; Halliday JL
J Med Screen; 2006; 13(1):8-13. PubMed ID: 16569299
[TBL] [Abstract][Full Text] [Related]
34. [Serum screening in pregnant women for Down syndrome and open neural-tube defects; testing against the Health Council criteria for genetic screening].
Wildhagen MF; Christiaens GC; Habbema JD
Ned Tijdschr Geneeskd; 1996 Jan; 140(2):85-9. PubMed ID: 8569927
[TBL] [Abstract][Full Text] [Related]
35. [Prenatal diagnosis of trisomy 21].
Massé J; Forest JC
Ann Biol Clin (Paris); 1990; 48(8):536-40. PubMed ID: 1705107
[TBL] [Abstract][Full Text] [Related]
36. Participation in maternal serum screening for Down syndrome, neural tube defects, and trisomy 18 following screen-positive results in a previous pregnancy.
Rausch DN; Lambert-Messerlian GM; Canick JA
West J Med; 2000 Sep; 173(3):180-3. PubMed ID: 10986181
[TBL] [Abstract][Full Text] [Related]
37. The triple-marker test in predicting fetal aneuploidy: a compromise between sensitivity and specificity.
Huderer-Duric K; Skrablin S; Kuvacic I; Sonicki Z; Rubala D; Suchanek E
Eur J Obstet Gynecol Reprod Biol; 2000 Jan; 88(1):49-55. PubMed ID: 10659916
[TBL] [Abstract][Full Text] [Related]
38. Refinements in managing maternal weight adjustment for interpreting prenatal screening results.
Neveux LM; Palomaki GE; Larrivee DA; Knight GJ; Haddow JE
Prenat Diagn; 1996 Dec; 16(12):1115-9. PubMed ID: 8994247
[TBL] [Abstract][Full Text] [Related]
39. Sensitivity and specificity of screening for Down syndrome with alpha-fetoprotein, hCG, unconjugated estriol, and maternal age.
Macri JN; Kasturi RV; Krantz DA; Cook EJ
Obstet Gynecol; 1991 Jun; 77(6):963-5. PubMed ID: 1709482
[No Abstract] [Full Text] [Related]
40. Maternal serum second trimester screening for chromosomal disorders and neural tube defects in a government hospital of North India.
Kaur G; Srivastav J; Kaur A; Huria A; Goel P; Kaur R; Kataria S; Chavan BS; Kochhar S; Aggarwal P; Kaur N; Panigrahi I; Chawla P
Prenat Diagn; 2012 Dec; 32(12):1192-6. PubMed ID: 23055346
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
